Alexander Doroshenko

Dr. Alexander Doroshenko is an infectious disease epidemiologist and public health specialist in Alberta, Canada. His interests include evaluation of public health interventions and evidence-based public health policies.

Doroshenko is the Public Health representative for the AHS COVID-19 Scientific Advisory Group under Alberta Health Services.¹⁾

Doroshenko is an Assistant Professor in the Department of Medicine, Faculty of Medicine and Dentistry at the University of Alberta.²⁾

He has received funding for research through the University of Alberta from the University Hospital Foundation, which is funded by Takeda, Biogen, Boehringer Ingelheim, Novartis, Merck, Volvo, Edmonton Journal, Canadian National Railway (part owned by Bill Gates), RBC (Royal Bank of Canada), TELUS, KPMG, Medtronic, Scotia Capital (Scotiabank), Postmedia, Deloitte, Fidelity, London Drugs, WestJet, Aecon, PricewaterhouseCoopers, Janssen, CTV News, Bell Media, Global News, Corus Entertainment, Astellas, Novo Nordisk, Servier, and Roche.^{3) 4) 5)}

• Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review⁶⁾
  • Funded by the SPOR Evidence Alliance, Canadian Institutes of Health Research (CIHR), and COVID-END.

• Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines)⁷⁾
  • Co-authored with Scott Halperin, who has an extensive catalogue of vaccine-related publications and was funded by Novartis for this study
  • In collaboration with the Canadian Center for Vaccinology

• What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model⁸⁾
  • Funded by Alberta Health Services and the University of Alberta

• Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures: Alberta, Canada⁹⁾
  • Doroshenko reported receiving personal fees from Sanofi for an advisory role
  • He also reported that his employer, the University of Alberta, was paid additional funds in research grants from the Canadian Institutes of Health Research (CIHR), Public Health Agency of Canada, Alberta Health Services, and the University Hospital Foundation (also listed as “University of Alberta Hospital Foundation”).
  • The study found that the public health measures Doroshenko helped put in place were “associated with a substantial reduction in influenza and NIRV infections in Alberta.”

• The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions-Ending the COVID-19 Pandemic¹⁰⁾
  • Doroshenko reported receiving personal fees from Sanofi for an advisory role
  • He also reported that his employer, the University of Alberta, was paid additional funds in research grants from the Canadian Institutes of Health Research (CIHR), Public Health Agency of Canada, Alberta Health Services, and the University Hospital Foundation (also listed as “University of Alberta Hospital Foundation”).